|
1
|
Zhu Y, Zhu L, Lu L, Zhang L, Zhang G, Wang
Q and Yang P: Role and mechanism of the alkylglycerone phosphate
synthase in suppressing the invasion potential of human glioma and
hepatic carcinoma cells in vitro. Oncol Rep. 1:431–436. 2014.
|
|
2
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brock MV, Hooker CM, Syphard JE, Westra W,
Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, et al:
Surgical resection of limited disease small cell lung cancer in the
new era of platinum chemotherapy: Its time has come. J Thorac
Cardiovasc Surg. 129:64–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao L, Li W, Zhou Y, Zhang Y, Huang S, Xu
X, Li Z and Guo Q: The overexpression and nuclear translocation of
Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and
GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis.
Free Radic Biol Med. 82:29–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T: Advances in target therapy
for lung cancer. Jpn J Clin Oncol. 40:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCarthy N: Cell cycle: A WEE pointer. Nat
Rev Cancer. 12:378–379. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pouliot LM, Chen YC, Bai J, Guha R, Martin
SE, Gottesman MM and Hall MD: Cisplatin sensitivity mediated by
WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer
Res. 72:5945–5955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kogiso T, Nagahara H, Hashimoto E,
Ariizumi S, Yamamoto M and Shiratori K: Efficient induction of
apoptosis by wee1 kinase inhibition in hepatocellular carcinoma
cells. PLoS One. 6:e1004952014. View Article : Google Scholar
|
|
10
|
Tsai SC, Yang JS, Peng SF, Lu CC, Chiang
JH, Chung JG, Lin MW, Lin JK, Amagaya S, Chung C Wai-Shan, et al:
Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell
death in SK-HEP-1 human hepatocellular carcinoma cells. Int J
Oncol. 4:1431–1442. 2012.
|
|
11
|
de Figueiredo-Pontes LL, Pintão MC,
Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP and Rego
EM: Determination of P-glycoprotein, MDR-related protein 1, breast
cancer resistance protein, and lung-resistance protein expression
in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin
Cytom. 74:163–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fridman E, Skarda J, Pinthus JH, Ramon J
and Mor Y: Expression of multidrug resistance-related protein
(MRP-1), lung resistance-related protein (LRP) and topoisomerase-II
(TOPO-II) in Wilms' tumor: Immunohistochemical study using TMA
methodology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
152:47–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kerr EH, Frederick PJ, Egger ME, Stockard
CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE,
Straughn JM, et al: Lung resistance-related protein (LRP)
expression in malignant ascitic cells as a prognostic marker for
advanced ovarian serous carcinoma. Ann Surg Oncol. 20:3059–3065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li K, Chen B, Xu L, Feng J, Xia G, Cheng
J, Wang J, Gao F and Wang X: Reversal of multidrug resistance by
cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung
cancer cells in vitro and in vivo. Int J Nanomedicine. 8:1867–1877.
2013.PubMed/NCBI
|
|
16
|
Surowiak P, Materna V, Kaplenko I,
Spaczyński M, Dietel M, Lage H and Zabel M: Augmented expression of
metallothionein and glutathione S-transferase pi as unfavourable
prognostic factors in cisplatin-treated ovarian cancer patients.
Virchows Arch. 447:626–633. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Liu XJ, Yang P, Zhao M, Lv LX,
Zhang GD, Wang Q and Zhang L: Alkylglyceronephosphate synthase
(AGPS) alters lipid signaling pathways and supports chemotherapy
resistance of glioma and hepatic carcinoma cell lines. Asian Pac J
Cancer Prev. 7:3219–3226. 2014. View Article : Google Scholar
|
|
18
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brozovic A and Osmak M: Activation of
mitogen-activated protein kinases by cisplatin and their role in
cisplatin-resistance. Cancer Lett. 251:1–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
